These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30474288)

  • 21. Lean nonalcoholic fatty liver disease and sarcopenia.
    Chen M; Cao Y; Ji G; Zhang L
    Front Endocrinol (Lausanne); 2023; 14():1217249. PubMed ID: 37424859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis.
    Chakravarthy MV; Siddiqui MS; Forsgren MF; Sanyal AJ
    Front Endocrinol (Lausanne); 2020; 11():592373. PubMed ID: 33424768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
    Mikolasevic I; Pavic T; Kanizaj TF; Bender DV; Domislovic V; Krznaric Z
    Can J Gastroenterol Hepatol; 2020; 2020():8859719. PubMed ID: 33204675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease.
    Iwaki M; Kobayashi T; Nogami A; Saito S; Nakajima A; Yoneda M
    Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice.
    El Sherif O; Dhaliwal A; Newsome PN; Armstrong MJ
    Expert Rev Gastroenterol Hepatol; 2020 Mar; 14(3):197-205. PubMed ID: 32064966
    [No Abstract]   [Full Text] [Related]  

  • 26. Interaction between sarcopenia and nonalcoholic fatty liver disease.
    Joo SK; Kim W
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S68-S78. PubMed ID: 36472051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity.
    Han E; Kim MK; Im SS; Jang BK; Kim HS
    J Diabetes Complications; 2022 Aug; 36(8):108253. PubMed ID: 35817677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review.
    Armandi A; Rosso C; Caviglia GP; Ribaldone DG; Bugianesi E
    Front Endocrinol (Lausanne); 2021; 12():716533. PubMed ID: 34858322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease.
    Zambon Azevedo V; Silaghi CA; Maurel T; Silaghi H; Ratziu V; Pais R
    Front Nutr; 2021; 8():774030. PubMed ID: 35111794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: An altered liver-muscle crosstalk leading to increased mortality risk.
    Kuchay MS; Martínez-Montoro JI; Kaur P; Fernández-García JC; Ramos-Molina B
    Ageing Res Rev; 2022 Sep; 80():101696. PubMed ID: 35843589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease.
    Hao XY; Zhang K; Huang XY; Yang F; Sun SY
    World J Gastroenterol; 2024 Feb; 30(7):636-643. PubMed ID: 38515958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease.
    Golabi P; Gerber L; Paik JM; Deshpande R; de Avila L; Younossi ZM
    JHEP Rep; 2020 Dec; 2(6):100171. PubMed ID: 32964202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sarcopenic obesity in fatty liver.
    Merli M; Lattanzi B; Aprile F
    Curr Opin Clin Nutr Metab Care; 2019 May; 22(3):185-190. PubMed ID: 30893090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic-Associated Fatty Liver Disease and Sarcopenia.
    Bali T; Chrysavgis L; Cholongitas E
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):497-508. PubMed ID: 37495340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011).
    Lee YH; Jung KS; Kim SU; Yoon HJ; Yun YJ; Lee BW; Kang ES; Han KH; Lee HC; Cha BS
    J Hepatol; 2015 Aug; 63(2):486-93. PubMed ID: 25772036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential Impact of Weight Loss on Nonalcoholic Fatty Liver Resolution in a North American Cohort with Obesity.
    Rachakonda V; Wills R; DeLany JP; Kershaw EE; Behari J
    Obesity (Silver Spring); 2017 Aug; 25(8):1360-1368. PubMed ID: 28605159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study.
    Kim G; Lee SE; Lee YB; Jun JE; Ahn J; Bae JC; Jin SM; Hur KY; Jee JH; Lee MK; Kim JH
    Hepatology; 2018 Nov; 68(5):1755-1768. PubMed ID: 29679374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis.
    Deng C; Ou Q; Ou X; Pan D
    BMJ Open; 2024 May; 14(5):e078933. PubMed ID: 38719326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.
    Ooi GJ; Mgaieth S; Eslick GD; Burton PR; Kemp WW; Roberts SK; Brown WA
    Obes Rev; 2018 Feb; 19(2):281-294. PubMed ID: 29119725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis.
    Yu R; Shi Q; Liu L; Chen L
    BMC Gastroenterol; 2018 Apr; 18(1):51. PubMed ID: 29673321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.